此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Clinical Study on Tissue Preservation in Breast Augmentation and Reconstruction

2026年5月28日 更新者:Establishment Labs

Post-Marketing Clinical Follow-Up Study on Tissue Preservation Techniques in Breast Augmentation and Reconstruction.

This clinical study aims to evaluate the safety and effectiveness of advanced, minimally invasive techniques for breast augmentation and reconstruction. These methods, known as Mia Harmonization, Mia Scarless Lift, Mia Reconstruction, Joy Dot, and Maxtopexia + Mia, focus on preserving breast tissue, reducing recovery time, and improving aesthetic outcomes.

研究概览

详细说明

This post-marketing observational study evaluates the safety and efficacy of innovative, minimally invasive breast augmentation and reconstruction techniques: Mia Harmonization, Mia Scarless Lift, Mia Reconstruction, Joy Dot, and Maxtopexia + Mia. These techniques aim to enhance tissue preservation, minimize scarring, and promote quicker recovery compared to traditional methods.

The study will enroll 60 participants undergoing these procedures at the Sulàyöm Innovation Campus in Costa Rica between January and December 2025. Participants will be followed for 36 months to monitor complication rates, tissue health, and satisfaction. Procedures utilize advanced devices like the Motiva Ergonomix2® Diamond®, Motiva Injector®, Motiva® Inflatable Balloon, and Motiva® Reusable Channel Separator, designed to optimize outcomes while preserving natural breast structures.

Key assessments include:

Safety Metrics: Monitoring adverse events, such as tissue necrosis, hematoma, or infection, through regular follow-ups.

Efficacy Metrics: Evaluating tissue preservation during and after surgery using imaging and clinical assessments.

Patient and Surgeon Satisfaction: Measuring perceptions of outcomes and procedure success using validated scales.

The study will also conduct a temperature monitoring substudy using the Motiva® Zen transponder to assess its functionality in recording implant temperature. This optional component enhances understanding of implant safety.

Results will provide crucial insights into the role of minimally invasive techniques in improving breast surgery outcomes, focusing on safety, tissue preservation, and patient satisfaction. These findings will inform future surgical practices and technological advancements.

研究类型

观察性的

注册 (估计的)

60

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Alajuela Province
      • Coyol、Alajuela Province、哥斯达黎加、20113
        • Establishment Labs

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

取样方法

非概率样本

研究人群

The study population comprises approximately 60 cisgender women aged 18 years or older who will undergo minimally invasive breast augmentation or benign reconstruction procedures at the Sulàyöm Innovation Campus in Costa Rica.

Eligible participants will include women with breast cup sizes ranging from AA to C, classified as ASA I or II, and with sufficient breast tissue to support implant placement. The cohort will include individuals undergoing the following procedures:

  • Mia Harmonization
  • Mia Scarless Lift
  • Mia Reconstruction
  • Joy Dot
  • Maxtopexia + Mia Additionally, participants may have congenital or acquired breast conditions (e.g., amastia, tuberous breasts, asymmetry) and meet the specific inclusion criteria for these advanced minimally invasive techniques.

Recruitment will focus on women scheduled for surgery between January and December 2025, with follow-up spanning 36 months. Participants must reside in Costa Rica to ensure adherence to follow-up visits.

描述

Inclusion Criteria:

  1. Gender and Age: Cisgender women, aged 18 years or older.
  2. Surgical Procedure: Participants undergoing primary breast augmentation or benign reconstruction using the following minimally invasive procedures:

    • Mia Harmonization
    • Mia Scarless Lift
    • Mia Reconstruction
    • Joy Dot
    • Maxtopexia + Mia
  3. Breast Size: Cup sizes AA to C, as determined by guidelines from Triumph International.
  4. Health Status: ASA (American Society of Anesthesiologists) classification I or II.
  5. Tissue Integrity: Adequate breast tissue available to cover the implant(s).
  6. Commitment: Willingness to adhere to all study requirements, including follow-up visits and signing the informed consent form.
  7. Special Cases for Reconstruction: Participants with congenital or acquired breast or thoracic conditions, such as amastia, pectus excavatum/carinatum, tuberous breasts, or asymmetry.
  8. Mia Scarless Lift Specifics: Participants with mild, moderate, or pseudoptosis based on physician evaluation.
  9. Timing: Women scheduled for surgery at the Sulàyöm Innovation Campus between January and December 2025.

Exclusion Criteria:

  1. Non-Specified Procedures: Women undergoing augmentation or reconstruction with techniques other than those listed (Mia Harmonization, Mia Scarless Lift, Mia Reconstruction, Joy Dot, Maxtopexia + Mia).
  2. Non-Study Implants: Use of implants other than Motiva products.
  3. Compromised Tissue or Skin:

    • Existing rib lesions or significant/severe breast ptosis.
    • Poor tissue quality due to radiation damage, vascular compromise, or prior ulceration.
  4. Medical History:

    • History of breast abscesses or infections.
    • Sensitivity or allergy to silicone.
  5. Current Physiological Conditions:

    -Pregnancy or breastfeeding, or within six months postpartum or post-lactation.

  6. Medications: Use of anticoagulants or medications that impair wound healing (e.g., corticosteroids, Warfarin).
  7. Imaging Constraints: Conditions that prevent the use of MRI (e.g., implanted metal devices, claustrophobia).
  8. Concurrent Research: Participation in another clinical research study involving drugs or devices.
  9. Follow-Up Barriers: Residency outside Costa Rica or inability to attend required follow-up visits.
  10. Timing Issues: Participants undergoing surgery outside the designated study period (January to December 2025).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Minimally Invasive Breast Surgery Cohort
This single cohort consists of approximately 60 women undergoing one of the minimally invasive breast augmentation or reconstruction procedures (Mia Harmonization, Mia Scarless Lift, Mia Reconstruction, Joy Dot, or Maxtopexia + Mia) at the Sulàyöm Innovation Campus. Data from all participants will be analyzed collectively to evaluate the safety, efficacy, and outcomes of these procedures.
Minimally invasive technique for breast augmentation, increasing volume while preserving natural tissue.
Minimally invasive breast lift for mild to moderate ptosis without visible scarring.
Reconstructive technique for restoring breast contour and volume after benign surgical interventions.
Advanced augmentation method using specialized tools to preserve tissue integrity and minimize trauma.
Breast lift combining traditional techniques with advanced minimally invasive methods for tissue preservation.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of Adverse Events Related to Tissue Preservation
大体时间:36 months post-surgery.
The cumulative occurrence of adverse events, such as necrosis, hematoma, infection, or tissue damage, associated with the surgical procedures.
36 months post-surgery.
Rate of Intraoperative Tissue Integrity Preservation
大体时间:Day of surgery.
Proportion (%) of surgical procedures in which intraoperative tissue integrity is maintained (no damage observed), and incidence rate (%) of tissue damage events during surgery, as assessed intraoperatively.
Day of surgery.

次要结果测量

结果测量
措施说明
大体时间
Patient-Reported Satisfaction Score (5-Point Likert Scale)
大体时间:Baseline and follow-ups at 1, 3, 6, 12, 24, and 36 months post-surgery.
Mean score and distribution of patient-reported satisfaction with breast appearance, natural feel, and symmetry, measured using a 5-point Likert scale.
Baseline and follow-ups at 1, 3, 6, 12, 24, and 36 months post-surgery.
Surgeon-Reported Satisfaction Score (5-Point Likert Scale)
大体时间:Day of surgery.
Mean score and distribution of surgeon-reported satisfaction with breast appearance, natural feel, and symmetry, measured using a 5-point Likert scale.
Day of surgery.
Rate of Postoperative Complications
大体时间:36 months post-surgery.
Incidence rate (%) of postoperative complications, including fibrosis, capsular contracture, and scarring, during the follow-up period.
36 months post-surgery.

其他结果措施

结果测量
措施说明
大体时间
Patient-Reported Pain Score (Standardized Pain Scale)
大体时间:Baseline and follow-ups at 1, 3, 6, 12, 24, and 36 months post-surgery.
Mean patient-reported pain score measured using a standardized pain scale at each follow-up visit.
Baseline and follow-ups at 1, 3, 6, 12, 24, and 36 months post-surgery.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年5月1日

初级完成 (估计的)

2026年12月31日

研究完成 (估计的)

2029年2月28日

研究注册日期

首次提交

2025年8月20日

首先提交符合 QC 标准的

2026年5月28日

首次发布 (实际的)

2026年6月3日

研究记录更新

最后更新发布 (实际的)

2026年6月3日

上次提交的符合 QC 标准的更新

2026年5月28日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual Participant Data (IPD) will not be shared to ensure the confidentiality and privacy of participants. Since the study collects sensitive clinical data, strict measures are in place to protect participant identities. Data will be securely stored in a de-identified and encrypted format, accessible only to authorized research personnel. This approach aligns with ethical standards and local regulations, such as Costa Rica's Ley de Investigación Biomédica (Law 9234), which prioritizes the protection of participants' personal information.

Additionally, as this is an observational study with no direct interventions, the value of sharing IPD for broader scientific purposes is limited compared to the aggregate analysis and results.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅